TP53 and ovarian carcinoma: Based on above results, our study suggests that STAT3 controls ovarian cancer cisplatin resistance through the ERS-mediated autophagy and a crosstalk with p53 and RAS signaling molecules including MAPK and PI3K/AKT, which may be targeted along with cisplatin treatment for ovarian cancer.